-

06:07:33 PM

CANF Stock News

CANF - Can-Fite Biopharma Ltd

01/24/23 7:00 AM

AMEX : CANF

clinical triallow float

Can-Fite: Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies—A Patent Has Been Filed

Data show significant anti-cancer effect in pancreatic carcinoma as a monotherapy and an additive effect when combined with gemcitabine, the standard-of-care chemotherapy for pancreatic cancer Namodenoson’ s excellent safety profile and its ability to directly inhibit the growth of pancreatic tumors present its potential as an effective drug for the...

RHEA-AI

neutral

01/11/23 9:04 AM

AMEX : CANF

offeringlow float

Can-Fite Announces $7.5 Million Concurrent Registered Direct Offering and Private Placement

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that it has entered into definitive agreements for the purchase and sale of 1,000,000 of the Company’ s American Depositary Shares, at a purchase price of $5.50...

RHEA-AI

neutral

01/10/23 7:00 AM

AMEX : CANF

low float

Can-Fite Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; FDA Submission to Follow

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced today...

RHEA-AI

very positive

12/30/22 4:30 PM

AMEX : CANF

low float

Can-Fite Announces ADS Ratio Change

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced today that the Company will change the ratio of its American Depositary Shares to ordinary shares from one ADS representing thirty ordinary shares to a new ratio of...

RHEA-AI

neutral

12/28/22 7:00 AM

AMEX : CANF

low float

Can-Fite Updates: Namodenoson Increases Survival for the Most Severe Patients with Advanced Liver Cancer

Results to be shared at Biotech Showcase during JP Morgan conference week in San Francisco and at BI0-CEO in New York An advanced CPB liver cancer patient remains clear of cancer 6 years following treatment with Namodenoson While CPB patients are typically excluded from liver cancer clinical studies due to low expected response rates,...

RHEA-AI

very positive

12/08/22 7:00 AM

AMEX : CANF

clinical triallow float

Can-Fite’s Partner Vetbiolix is Heading into a European Multicentric Clinical Trial with Piclidenoson for the Treatment of Pets’ Osteoarthritis

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced progress achieved in the development of Piclidenoson for` the treatment of...

RHEA-AI

positive

11/25/22 7:00 AM

AMEX : CANF

earningslow float

Can-Fite Reports Third Quarter 2022 Financial Results & Provides Clinical Update

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended September 30, 2022. The patient was in the Namodenoson arm of the Phase II study and continued treatment with...

RHEA-AI

neutral

11/02/22 7:15 AM

AMEX : CANF

low float

Can-Fite: Positive New Data from it’s Phase III Psoriasis Study will be Presented Today at an Industry Expert Summit in Boston

The Summit will host industry drug development experts, all in the dermatology arena, who will present their technologies, exchange views and look at potential collaborations and partnerships. Phase III COMFORT study successfully met its primary efficacy endpoint with Piclidenoson showing a safety profile similar to placebo and better tolerated than...

RHEA-AI

neutral

10/25/22 7:00 AM

AMEX : CANF

low float

Can-Fite: Findings Showing the Complete Clearance of Cancer in Patient Treated With Namodenoson Will Be Presented at the AASLD Liver Meeting®

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced today that a poster entitled“ Complete Response Induced by Namodenoson, an A3...

RHEA-AI

neutral

10/13/22 7:00 AM

AMEX : CANF

conferenceslow float

Can-Fite to Present its Phase IIb NASH Drug Candidate Namodenoson at Upcoming Conference

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced today the Company’ s CEO Dr. There is currently no U.S. FDA approved treatment for NASH, an addressable pharmaceutical market estimated to reach $35-$40 billion by 2025...

RHEA-AI

neutral

1 2 3 4 5 6 7 8 Next